tt2001

Targeting Article: ATS Receives $900,000 in NIH Funding

In September, Advanced Targeting Systems received two Small Business Innovation Research (SBIR) awards from the National Institutes of Health. The first is a Phase II grant from the National Institute of Neurological Disorders and Stroke. This project continues a collaboration with Drs. Joanne Berger-Sweeney (Wellesley College) and Mark Baxter (Harvard University) to further develop the

Targeting Article: ATS Receives $900,000 in NIH Funding Read More »

Cover Article: Immunolesioning Hippocampal Inhibitory Interneurons

Dr. Robert Sloviter, University of Arizona, contributes this issue’s article from the laboratories of ATS customers. Dr. Sloviter summarizes his research with SSP-saporin, which he and his graduate student Jennifer Martin used to examine the role of inhibitory neurons in maintaining normal network excitability. The mammalian hippocampus is perhaps the most intensely studied brain region

Cover Article: Immunolesioning Hippocampal Inhibitory Interneurons Read More »

Cover Article: Dermorphin-SAP Kills MOR-Positive Cells

Advanced Targeting Systems announces the release of its new, very exciting targeted toxin, dermorphin-SAP. It is a conjugate of the mu opioid receptor (MOR) agonist dermorphin and the ribosome-inactivating protein, saporin. Its cytotoxicity to cells that express the MOR promise to make it an important tool in the discovery and definition of the role of

Cover Article: Dermorphin-SAP Kills MOR-Positive Cells Read More »

Safety Studies Begin

Early last month (March 2001), Advanced Targeting Systems (ATS) received funding from the National Institute of Mental Health (NIMH) to begin toxicology/safety studies of Substance P-Saporin (SP-SAP), a potential therapeutic for the treatment of chronic pain. The studies will be completed under the direction of three scientists who are experts in their respective fields. Dr.

Safety Studies Begin Read More »

Cover Article: Immunolesioning – From Spinal Cord to Brain

Contributed by Dr. Ann Schreihofer, University of Virginia, contributes this issue’s article from the laboratories of ATS customers. Dr. Schreihofer summarizes her research with anti-DBH-SAP (Cat. #IT-03) to immunolesion specific rostral ventral medulla neurons that project to the spinal cord by injection of anti-DBH-SAP into the rat spinal cord. The toxin is taken up and

Cover Article: Immunolesioning – From Spinal Cord to Brain Read More »

Shopping Cart
Scroll to Top